NASDAQ · STOCK

Regeneron Pharmaceuticals

REGN Biotechnology Unknown Updated July 08, 2026
$665.71
52W $532.60 – $821.11
56/100
$70,790
15.8
0.20
AI Committee Verdict
Lean Buy
+12.8%
-2.7%
4.82:1
65%
Bull & Bear Case
Bull Case
  • Positive MACD histogram signals bullish momentum.
  • Daily volatility (ATR%) above ~3% is treated as elevated risk.
Bear Case
  • Stochastic RSI (84.4) confirms overbought conditions.
  • Both daily and weekly trends are bearish — strong multi-timeframe downtrend.
AI Investment Committee
Committee Consensus As of July 08, 2026
Overall Committee Score
56/100
The AI Investment Committee is an ensemble of six specialized analytical agents: Value Analyst, Technical Analyst, Growth Analyst, Risk Analyst, Macro Analyst, and News Analyst. Each agent independently evaluates REGN using dedicated data signals, then the committee aggregates their verdicts into a final score and recommendation. This multi-agent approach reduces individual model bias and provides a more balanced investment assessment.
View Full Committee Breakdown in Terminal →
Technical Analysis
RSI (14)
66.3
Neutral
MACD Histogram
8.407
Bullish Momentum
Trend Direction
Sideways
Weekly: Downtrend
Market Structure
Mixed
Support
$645.19
Resistance
$747.75
Bollinger %B
0.96
Inside Bands
Price vs Moving Averages
EMA 9
$646.12 Above
EMA 21
$637.09 Above
EMA 50
$655.08 Above
EMA 200
$690.10 Below
Fundamental Analysis
Valuation
90
Growth
42
Profitability
93
Financial Health
100
Valuation
P/E Ratio 15.8×
P/B Ratio 2.60×
PEG Ratio
Dividend Yield 0.56%
52W High $821.11
52W Low $532.60
Quality & Growth
ROE 1432.0%
ROA 1107.0%
Gross Margin 8570.0%
Operating Margin 2432.0%
Revenue Growth YoY +592.0%
Debt / Equity 0.09
AI Fundamental Assessment
[reduced confidence: limited earnings history] P/E ratio of 15.8 (inexpensive relative to a 15-40x range); Price-to-book of 2.6x; Revenue growth (YoY) of 5.9%; EPS growth (YoY) of 4.4%; Return on equity of 14.3%; Return on assets of 11.1%; Net margin of 29.6%; Gross margin of 85.7%; Current ratio of 4.13 (healthy short-term liquidity); Debt-to-equity of 0.09; Earnings-history trend unavailable; growth based on TTM year-over-year only.
Key Risks
  • Stochastic RSI (84.4) confirms overbought conditions.
  • Both daily and weekly trends are bearish — strong multi-timeframe downtrend.
This risk summary is generated from quantitative data signals, not qualitative opinion. All investors should conduct their own due diligence. This is not financial advice.
Get the Full REGN Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal → Mobile